Septerna Inc.
May 14, 2025 - by Joey Ramson
$SEPN is up today after it was announced that Novo Nordisk has struck a collaboration and licensing deal with them to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.2 billion for Septerna.
